Company: DARE
Filing Date: 2025-04-24
Form Type: ARS
Source: 0001401914-25-000018
Chunk: 317

Company: Dare Bioscience, Inc.
Filing Date: 2025-04-24
Form: ARS
Chunk 317
---
 funding liability also includes grant funds spent but not yet expensed in accordance with GAAP. The Company must track expenses incurred under the award and submit a detailed accounting of such expenses. Through December 31, 2024, the Company received one payment of $1.0 million under this award. The Company recorded credits to research and development expense of approximately $0.4 million for costs related to this award for the year ended December 31, 2024. As of December 31, 2024, the Company has recorded approximately $0.6 million of deferred grant funding liability in the Company's consolidated balance sheets. NICHD and NIH Non-Dilutive Grant Funding The Company has received notices of awards and non-dilutive grant funding from the NICHD and the National Institutes of Health, or NIH, to support the development of several of its product candidates. The NICHD and NIH issue notices of awards to the Company for a specified amount, and the Company must incur and track expenses eligible for reimbursement under the award and submit a detailed accounting of such expenses to receive payment. If the Company receives payments under the award, the amounts of such payments are recognized in the statements of operations as a reduction to research and development activities as the related costs are incurred to meet those obligations over the period. F-33

DARE-HPV In December 2024, the Company received a notice of award from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the NIH, that the Company was awarded a $1.0 million grant in support of non-clinical activities for the development of DARE-HPV for an initial project year of December 2024 through November 2025, and that an additional $1.0 million was recommended for the subsequent project year, subject to the availability of funds and satisfactory progress of the project, as determined by NIAID. The Company recorded no credits to research and development expense for costs related to the NIH award for the year ended December 31, 2024 and recorded no receivable at December 31, 2024. DARE-PTB1 In August 2020, the Company received a notice of award from NICHD to support the development of DARE- PTB1. The award of approximately $0.3 million was used for what was referred to as the "Phase I" segment of the project outlined in the Company's grant application, which ended in July 2023. The Company received aggregate reimbursements